Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com​

Articles

CDK4/6 Inhibitors Continue to Revolutionize ER+ Breast Cancer Care

July 16th 2018

Yelena Novik, MD, discusses the application of CDK4/6 inhibition and methods to overcome resistance in ER-positive breast cancer.

State of Immunotherapy Continues to Shift in NSCLC

July 13th 2018

Liza C. Villaruz, MD, addresses the immunotherapy clinical trials that have informed the treatment of patients with NSCLC and the current state of biomarkers in the field.

Expert Stresses Importance of Genetic Testing in Ovarian Cancer

July 12th 2018

Deborah Krakow, MD, discusses the value of a patient’s family history and its implications on genetic counseling.

Pietras Presents Pillars of Palliative Care in Ovarian Cancer

July 12th 2018

Christopher J. Pietras, MD, discusses the elements of palliative care for patients with ovarian cancer.

Antibody-Directed Therapeutic Research Ongoing in Ovarian Cancer

July 12th 2018

Sanaz Memarzadeh, MD, PhD, details the early developments of antibody-directed therapies and restoring p53 function in the treatment of patients with ovarian cancer.

Expert Tracks the Activity of PARP Inhibitors in Ovarian Cancer

July 11th 2018

Gottfried E. Konecny, MD, discusses developments in the understanding of response to PARP inhibition in ovarian cancer.

Efforts Continue to Increase Immunotherapy Impact in Gynecologic Cancers

July 10th 2018

John A. Glaspy, MD, discusses challenges and progress with immunotherapy in gynecologic cancers.

Optimal Duration of Adjuvant Endocrine Therapy Undecided in ER+ Breast Cancer

July 10th 2018

Maryann J. Kwa, MD, discusses the optimal duration of endocrine therapy in the treatment of patients with early-stage ER-positive breast cancer.

Optimal Use With Adjuvant Endocrine Therapy Continues to Unfold in ER+ Breast Cancer

July 9th 2018

Alex E. Denes, MD, discusses the mixed results looking at the optimal duration of adjuvant endocrine therapy in postmenopausal women with breast cancer.

Liu Looks Beyond Resistance in ALK-Translocated NSCLC

July 6th 2018

Stephen Liu, MD, addresses the use of available therapies and the methods of overcoming acquired resistance in patients with ALK-positive non–small cell lung cancer.

Expert Elaborates on Emerging Advances in Bladder Cancer Care

July 6th 2018

Petros Grivas, MD, PhD, discusses ongoing clinical trials exploring novel approaches with the potential to change practice in advanced bladder cancer.

Expert Highlights Ongoing Efforts for TNBC Treatment

July 6th 2018

David B. Page, MD, discusses emerging treatment approaches for patients with triple-negative breast cancer.

Esteva Recaps Advances in HER2-Targeted Therapy in Breast Cancer

July 6th 2018

Francisco J. Esteva, MD, PhD, discusses recent advances and clinical findings with HER2-targeted therapies across the neoadjuvant, adjuvant, and metastatic settings.

Sequencing Challenges Persist in Metastatic Prostate Cancer

July 5th 2018

Scott Samuelson, MD, discusses frontline treatment of patients with prostate cancer and subsequent sequencing.

Slamon Specifies Next Steps in Ovarian Cancer Treatment

July 3rd 2018

Dennis J. Slamon, MD, PhD, discusses new opportunities for treatment advances in ovarian cancer.

Bazhenova Highlights Treatments for ALK+ NSCLC, Less Common Drivers

June 29th 2018

Lyudmila A. Bazhenova, MD, discusses treatments for patients with ALK-positive NSCLC, as well as the progress in less common oncogenic drivers, such as NTRK fusions.

Expert Elaborates on Developments in SCLC and EGFR-Mutant NSCLC

June 28th 2018

Kathryn A. Gold, MD, discusses the evolving management of EGFR-mutant non–small cell lung cancer and the latest developments in small cell lung cancer.

Expert Highlights Ongoing Research and Challenges in Pancreatic Cancer

June 27th 2018

Ramesh K. Ramanathan, MD, discusses sequencing strategies and emerging therapeutic targets in pancreatic cancer.

Grothey Grapples With Treatment Options in mCRC

June 26th 2018

Axel Grothey, MD, discusses sidedness and first- and second-line treatments for patients with metastatic colorectal cancer.

O'Neil Shares Insight on Growing Therapeutic Arsenal for GI Tract NETs

June 25th 2018

Bert H. O’Neil, MD, discusses the prevalence of neuroendocrine tumors and the agents that are used to treat patients who present with them.

NEXT PAGE
PREVIOUS PAGE